GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (HKSE:06669) » Definitions » Net-Net Working Capital

Acotec Scientific Holdings (HKSE:06669) Net-Net Working Capital : HK$2.61 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Acotec Scientific Holdings Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Acotec Scientific Holdings's Net-Net Working Capital for the quarter that ended in Dec. 2023 was HK$2.61.

The industry rank for Acotec Scientific Holdings's Net-Net Working Capital or its related term are showing as below:

HKSE:06669's Price-to-Net-Net-Working-Capital is ranked better than
73.59% of 443 companies
in the Medical Devices & Instruments industry
Industry Median: 6.09 vs HKSE:06669: 2.88

Acotec Scientific Holdings Net-Net Working Capital Historical Data

The historical data trend for Acotec Scientific Holdings's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acotec Scientific Holdings Net-Net Working Capital Chart

Acotec Scientific Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
-0.09 -1.45 4.26 3.60 2.61

Acotec Scientific Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.93 3.60 2.80 2.61 -

Competitive Comparison of Acotec Scientific Holdings's Net-Net Working Capital

For the Medical Devices subindustry, Acotec Scientific Holdings's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acotec Scientific Holdings's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acotec Scientific Holdings's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Acotec Scientific Holdings's Price-to-Net-Net-Working-Capital falls into.



Acotec Scientific Holdings Net-Net Working Capital Calculation

Acotec Scientific Holdings's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(961.659+0.75 * 157.114+0.5 * 165.115-344.025
-0-0)/313.389
=2.61

Acotec Scientific Holdings's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

Net-Net Working Capital(Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(961.659+0.75 * 157.114+0.5 * 165.115-344.025
-0-0)/313.389
=2.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Acotec Scientific Holdings  (HKSE:06669) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Acotec Scientific Holdings Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Acotec Scientific Holdings's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Acotec Scientific Holdings Business Description

Traded in Other Exchanges
Address
16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN
Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.
Executives
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Nexus Partners Group Limited 2201 Interest of corporation controlled by you
Cosmic Elite Holdings Limited 2101 Beneficial owner
Li Jing 2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p. 2201 Interest of corporation controlled by you
Cpe Funds Iii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment Iii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment Ii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment (cayman) Limited 2101 Beneficial owner
Cpe Holdings Limited 2201 Interest of corporation controlled by you
Cpe Holdings International Limited 2201 Interest of corporation controlled by you
Cpe Gof Gp Limited 2201 Interest of corporation controlled by you
Cpe Global Opportunities Fund, L.p. 2201 Interest of corporation controlled by you
Boston Scientific Corporation 2201 Interest of corporation controlled by you
Cpechina Fund Iii, L. P.

Acotec Scientific Holdings Headlines

No Headlines